Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients Ivar AI

Ambcrypto.com

Crypto market cap surpasses France, UK GDPs – India, Japan next

Investor's Business Daily

Rambus Stock Is In A Buy Zone With Its Profits Soaring

VOA News

Ethnic armed group claims capture of key western Myanmar border

GlobeNewswire

Cell and Gene Therapy Market is expected to reach a revenue of USD 111.4 Bn by 2033, at 19.3% CAGR: Dimension Market Research

Zdnet.co.kr

애플, 사상 최고가...시총 3조7000억 달러 돌파

Bitcoinist

Crypto Fund Flows Hit $3.85 Billion Weekly Record As Bitcoin And Ethereum Dominate

Biztoc.com

Mark Zuckerberg's Soaring Wealth: Billionaire Now Richer Than Warren Buffett, Mark Cuban, Peter Thiel And Ken Griffin Combined

Robb Report

Google Just Made a Breakthrough in Quantum Computing With Its New Chip

Livedoor.com

ビットコイン価格は2024年1月から120％超上昇して10万ドルを突破、トランプ次期大統領の誕生・ETF需要・4月の半減期などが影響か

BusinessLine

India may attract share of $36-trillion principal investor capital: BCG

Bleeding Cool News

Moana 2 Powers Another Weekend Box Office Of Records

Biztoc.com

Taiwan Semi November Revenue Ups 34% Strengthened by AI and Smartphone Demand

Forbes

The Push And Pull Of Sino-American Chip Politics

Www.abc.es

La carta secreta de Putin, el Cosmos 2553, precursor de un arma espacial sin precedentes que amenazaría al mundo

Techpowerup.com

Micron Receives $6.1B in CHIPS Act Funding to Boost US Memory Manufacturing

Biztoc.com

Bill Gates: How Entrepreneurs Can Benefit From Climate Change

CryptoSlate

Bitcoin poised for ‘golden age’ in 2025 with $200k milestone projection – Bitwise

Milenio

Google invierte 800 millones en Intersect Power

Electrek

A record $847M raise powers a commercial rooftop solar wave

$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

GlobeNewswire

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma